October 11, 2017
Article
A lack of biomarkers can result in a delay in multiple sclerosis diagnosis and treatment.
October 04, 2017
The neurodegenerative phase of multiple sclerosis remains a significant challenge for researchers.
September 08, 2017
New FDA-approved drugs are members of a new class of vesicular monoamine transporter-2 inhibitors developed to address movement disorders.
June 07, 2017
FDA approval of valbenazine (Ingrezza) for the iatrogenic movement disorder tardive dyskinesia shows impact of a well-executed development program.
May 24, 2017
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in older people.
Dark adaptation testing has been shown to be better than visual acuity testing in diagnosing and staging AMD.